Fig. 2From: Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled studyRatio of cerebrospinal fluid (CSF) and unbound plasma atabecestat (JNJ-54861911) concentration in Caucasian patients with preclinical Alzheimer’s disease (AD) and patients with mild cognitive impairment (MCI) due to AD (ALZ1005), by dose groupBack to article page